Stockscreener 앱 받기
1.68
8.39%
0.13
시간 외 거래:
1.68
전일 마감가:
$1.55
열려 있는:
$1.55
하루 거래량:
3.08M
Relative Volume:
0.92
시가총액:
$231.13M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-1.5701
EPS:
-1.07
순현금흐름:
$-75.59M
1주 성능:
+7.01%
1개월 성능:
-44.19%
6개월 성능:
-65.43%
1년 성능:
-46.15%
1일 변동 폭
$1.55
$1.70
1주일 범위
$1.43
$1.70
52주 변동 폭
$1.15
$9.97
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.68 | 231.13M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte chief commercial officer purchases $9,999 in common stock - Investing.com Australia
Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know - MSN
Humacyte chief commercial officer purchases $9,999 in common stock By Investing.com - Investing.com UK
Press Release Distribution & PR Platform - ACCESS Newswire
Humacyte CFO Dale Sander buys $30,600 in company stock - Investing.com Australia
Humacyte CFO Dale Sander buys $30,600 in company stock By Investing.com - Investing.com South Africa
Humacyte’s chief medical officer acquires $11,625 in common stock By Investing.com - Investing.com South Africa
Humacyte’s chief medical officer acquires $11,625 in common stock - Investing.com Australia
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders - ACCESS Newswire
Small-Caps Explode Higher As Tariff Fears Ease: Humacyte, Forward Air, FormFactor Top Russell 2000 - Benzinga
Investigation announced for Investors who hold shares of Humacyte, Inc. (NASDAQ: HUMA) - openPR.com
Humacyte director Charles Green acquires $7,740 in stock - Investing.com Australia
Humacyte director Michael Constantino buys $20,160 in stock By Investing.com - Investing.com South Africa
Humacyte director Kathleen Sebelius acquires $66,000 in common stock By Investing.com - Investing.com South Africa
Humacyte director Michael Constantino buys $20,160 in stock - Investing.com
Humacyte director Charles Green acquires $7,740 in stock By Investing.com - Investing.com India
Humacyte director Kathleen Sebelius acquires $66,000 in common stock - Investing.com
Humacyte Executives Increase Holdings with Recent Purchases - TradingView
Humacyte, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should Know - MSN
Humacyte’s $50 Million Common Stock Offering - Global Legal Chronicle
HUMA stock touches 52-week low at $1.3 amid market challenges By Investing.com - Investing.com South Africa
Investors who lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Shareholders that Lost Money on Humacyte, Inc. (HUMA) Should Contact Levi & Korsinsky about Pending Class ActionHUMA - ACCESS Newswire
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - ACCESS Newswire
Humacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call Transcript - Insider Monkey
Humacyte’s Earnings Call: Balancing Achievements and Challenges - TipRanks
Humacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma Treatment - markets.businessinsider.com
symbol__ Stock Quote Price and Forecast - CNN
Benchmark maintains Buy rating, $17 target on Humacyte stock By Investing.com - Investing.com UK
Humacyte, Inc. Class Action: Levi & Korsinsky Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025HUMA - ACCESS Newswire
Benchmark maintains Buy rating, $17 target on Humacyte stock - Investing.com
Humacyte down following quarterly results, hits record low - MSN
Shareholders that lost money on Humacyte, Inc.(HUMA) should contact Levi & Korsinsky about pending Class ActionHUMA - ACCESS Newswire
Humacyte Stock Continues Slide Despite Lower Than Expected Q4 Loss – But Retail Gets More Bullish - MSN
Humacyte price target lowered to $8 from $10 at BTIG - Yahoo Finance
Humacyte’s Symvess Gains FDA Approval and Launches - TipRanks
Durham biotech defends lead product after concerns surface - The Business Journals
Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive By Investing.com - Investing.com South Africa
Humacyte shares tumble 10% as Q4 loss narrows but revenue remains elusive - Investing.com
Earnings call transcript: Humacyte Q4 2024 sees narrower EPS loss, stock edges up - Investing.com India
Humacyte Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.51%
자본화:
|
볼륨(24시간):